Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.66 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797406 | 0.93 | S1PR1 (0.60) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL177110 | 0.86 | S1PR1 (0.56) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15497196 | 0.86 | S1PR1 (0.60) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17797407 | 0.84 | S1PR1 (0.71) | S1PR1S1PR3 | |
| SCHEMBL9996209 | 0.84 | S1PR1 (0.77) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17797427 | 0.83 | S1PR1 (0.56) | S1PR1S1PR3 | |
| SCHEMBL17797404 | 0.80 | S1PR1 (0.63) | S1PR1S1PR3 | |
| SCHEMBL15661823 | 0.80 | S1PR1 (0.82) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL17805162 | 0.80 | S1PR1 (0.62) | S1PR1S1PR3 | |
| SCHEMBL29410964 | 0.79 | S1PR1 (1.00) | S1PR1S1PR3MAP4K4PRKCDMINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193716-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2015-11-24 | — | — | US | disclosed |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD. (AU) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885NPC1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.